Poly ICLC

{{Drugbox

| verifiedrevid = 464209114

| IUPAC_name =

| image =

| type = combo

| component1 = Carboxymethylcellulose

| class1 =

| component2 = Polyinosinic-polycytidylic acid

| class2 =

| component3 = Poly-L-lysine

| class3 =

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|UNII}}

| CAS_number = 59789-29-6

| ATC_prefix = L03

| ATC_suffix = AX08

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB17293

| UNII = 7KYP9TKT70

| chemical_formula =

| molecular_weight =

}}

Poly ICLC is an immunostimulant. It is polyinosinic-polycytidylic acid (poly I:C) mixed with the stabilizers carboxymethylcellulose and polylysine. It is under trial for use in cancer.{{cite web |title=Intervention Dynamic Trial Listing Page |url=https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/poly-iclc |website=National Cancer Institute |language=en |date=13 June 2017}}

Poly I:C is a ligand for toll like receptor-3, which usually triggers on the structurally similar double-stranded RNA present in some viruses.{{cite journal |vauthors=Zhu X, Nishimura F, Sasaki K, etal |title=Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models |journal=Journal of Translational Medicine |volume=5 |pages=10 |year=2007 |pmid=17295916 |doi=10.1186/1479-5876-5-10 |pmc=1802742 |doi-access=free }}